130 related articles for article (PubMed ID: 28049942)
1. Intranasal Administration of Rotenone to Mice Induces Dopaminergic Neurite Degeneration of Dopaminergic Neurons in the Substantia Nigra.
Sasajima H; Miyazono S; Noguchi T; Kashiwayanagi M
Biol Pharm Bull; 2017; 40(1):108-112. PubMed ID: 28049942
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration of rotenone in mice attenuated olfactory functions through the lesion of dopaminergic neurons in the olfactory bulb.
Sasajima H; Miyazono S; Noguchi T; Kashiwayanagi M
Neurotoxicology; 2015 Dec; 51():106-15. PubMed ID: 26493152
[TBL] [Abstract][Full Text] [Related]
3. Immunomorphological Changes in the Olfactory Bulbs of Rats after Intranasal Administration of Rotenone.
Voronkov DN; Kutukova KA; Ivanov MV; Khudoerkov RM
Bull Exp Biol Med; 2017 Dec; 164(2):203-206. PubMed ID: 29181664
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson's Like Symptoms Without Loss of Dopaminergic Neurons.
Sharma M; Kaur J; Rakshe S; Sharma N; Khunt D; Khairnar A
Neurotox Res; 2022 Feb; 40(1):215-229. PubMed ID: 34817799
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
6. Thallium-201 Imaging in Intact Olfactory Sensory Neurons with Reduced Pre-Synaptic Inhibition In Vivo.
Shiga H; Wakabayashi H; Washiyama K; Noguchi T; Hiromasa T; Miyazono S; Kumai M; Ogawa K; Taki J; Kinuya S; Miwa T
Mol Neurobiol; 2020 Dec; 57(12):4989-4999. PubMed ID: 32820461
[TBL] [Abstract][Full Text] [Related]
7. Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone.
Nesti C; Pardini C; Barachini S; D'Alessandro D; Siciliano G; Murri L; Petrini M; Vaglini F
Brain Res; 2011 Jan; 1367():94-102. PubMed ID: 20854799
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Rotenone Induces Alpha-Synuclein Accumulation, Neuroinflammation and Dopaminergic Neurodegeneration in Middle-Aged Mice.
Sharma M; Sharma N; Khairnar A
Neurochem Res; 2023 May; 48(5):1543-1560. PubMed ID: 36571663
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Systemic Exposure to Rotenone Induces Central and Peripheral Pathology of Parkinson's Disease in Mice.
Murakami S; Miyazaki I; Miyoshi K; Asanuma M
Neurochem Res; 2015 Jun; 40(6):1165-78. PubMed ID: 25894684
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of dopaminergic neurotoxins on DNA cleavage.
Tharakan B; Dhanasekaran M; Manyam BV
Life Sci; 2012 Jul; 91(1-2):1-4. PubMed ID: 22213117
[TBL] [Abstract][Full Text] [Related]
12. Neonatal systemic exposure to lipopolysaccharide enhances susceptibility of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life.
Cai Z; Fan LW; Kaizaki A; Tien LT; Ma T; Pang Y; Lin S; Lin RC; Simpson KL
Dev Neurosci; 2013; 35(2-3):155-71. PubMed ID: 23446007
[TBL] [Abstract][Full Text] [Related]
13. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
14. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
16. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice.
Richter F; Hamann M; Richter A
J Neurosci Res; 2007 Feb; 85(3):681-91. PubMed ID: 17171705
[TBL] [Abstract][Full Text] [Related]
17. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
18. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
19. Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria.
Cheng XY; Biswas S; Li J; Mao CJ; Chechneva O; Chen J; Li K; Li J; Zhang JR; Liu CF; Deng WB
Transl Neurodegener; 2020 Apr; 9(1):13. PubMed ID: 32345341
[TBL] [Abstract][Full Text] [Related]
20. Puerarin protects dopaminergic neurons in Parkinson's disease models.
Zhang X; Xiong J; Liu S; Wang L; Huang J; Liu L; Yang J; Zhang G; Guo K; Zhang Z; Wu P; Wang D; Lin Z; Xiong N; Wang T
Neuroscience; 2014 Nov; 280():88-98. PubMed ID: 25218963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
